Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 3/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.81 |
| ▸ | MAOB | P27338 | 5/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238401 | 0.92 | KDM4E (0.85) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4650072 | 0.91 | CYP3A4 (0.82) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| 6,3'-Dimethoxyflavone SCHEMBL516389 | 0.90 | KDM4E (0.82) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL30777197 | 0.90 | CYP3A4 (0.82) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL360247 | 0.90 | CYP3A4 (0.82) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| 6,3'-Dimethoxyflavone SCHEMBL30894690 | 0.90 | KDM4E (0.82) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| 7-Methoxyflavone SCHEMBL1373009 | 0.90 | TNKS (1.00) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL7124557 | 0.89 | CYP3A4 (0.80) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10068246 | 0.87 | KDM4E (0.78) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10037936 | 0.87 | CYP3A4 (0.78) | KDM4ECYP3A4ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| EP-4353264-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | Precvision Biotechnologies Ltd. (CN) | 2024-04-17 | — | — | EP | claimed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| WO-2022257986-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | claimed |
| US-8669048-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2014-03-11 | — | — | US | claimed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | claimed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | claimed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | claimed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | KDM4E 4389/4885CYP3A4 4355/4885ALDH1A1 2223/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | KDM4E 4335/4885CYP3A4 4539/4885ALDH1A1 2054/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | KDM4E 1732/4885CYP3A4 928/4885ALDH1A1 3285/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | KDM4E 2652/4885CYP3A4 1589/4885ALDH1A1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.